BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12050585)

  • 1. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease.
    Batres LA; Mamula P; Baldassano RN
    J Pediatr Gastroenterol Nutr; 2002 May; 34(5):558-60. PubMed ID: 12050585
    [No Abstract]   [Full Text] [Related]  

  • 2. Dermatologic manifestations of Crohn disease in children: response to infliximab.
    Kugathasan S; Miranda A; Nocton J; Drolet BA; Raasch C; Binion DG
    J Pediatr Gastroenterol Nutr; 2003 Aug; 37(2):150-4. PubMed ID: 12883301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab for peristomal pyoderma gangrenosum.
    Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
    Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
    Cocco A; Angelucci E; Viscido A; Caprilli R
    Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
    [No Abstract]   [Full Text] [Related]  

  • 5. Failure of sublesional infliximab injection for refractory parastomal pyoderma gangrenosum in a patient with Crohn's disease.
    Teich N
    Tech Coloproctol; 2014 Oct; 18(10):965-6. PubMed ID: 24965074
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of infliximab in pyoderma gangrenosum.
    Hewitt D; Tait C
    Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
    Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
    Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.
    Sapienza MS; Cohen S; Dimarino AJ
    Dig Dis Sci; 2004 Sep; 49(9):1454-7. PubMed ID: 15481318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Infliximab treatment of peristomal pyoderma gangrenosum in ulcerative colitis].
    Nybaek H; Jemec GB
    Ugeskr Laeger; 2005 Aug; 167(32):2920-1. PubMed ID: 16109221
    [No Abstract]   [Full Text] [Related]  

  • 10. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab.
    Grange F; Djilali-Bouzina F; Weiss AM; Polette A; Guillaume JC
    Dermatology; 2002; 205(3):278-80. PubMed ID: 12399677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
    Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
    Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyoderma gangrenosum and tumor necrosis factor α agents.
    Rallis E; Koumantaki-Mathioudaki E; Tsiatoura A; Stavropoulos P; Katsambas A
    Cutis; 2013 Oct; 92(4):E1-2. PubMed ID: 24195097
    [No Abstract]   [Full Text] [Related]  

  • 13. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.
    Ljung T; Staun M; Grove O; Fausa O; Vatn MH; Hellström PM
    Scand J Gastroenterol; 2002 Sep; 37(9):1108-10. PubMed ID: 12374238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease.
    Alkhouri N; Hupertz V; Mahajan L
    Inflamm Bowel Dis; 2009 Jun; 15(6):803-6. PubMed ID: 18942748
    [No Abstract]   [Full Text] [Related]  

  • 15. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
    Triantafillidis JK; Cheracakis P; Sklavaina M; Apostolopoulou K
    Scand J Gastroenterol; 2002 Jul; 37(7):863-5. PubMed ID: 12190104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
    Tanczos BT; Baumgart DC
    Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
    [No Abstract]   [Full Text] [Related]  

  • 17. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
    Stichweh DS; Punaro M; Pascual V
    Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Infliximab for a girl with refractory pyoderma gangrenosum].
    Nozawa T; Hara R; Kinoshita J; Sano F; Miyamae T; Imagawa T; Mori M; Hirokado M; Takahashi K; Inayama Y; Yokota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Dec; 31(6):454-9. PubMed ID: 19122376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of etanercept for postoperative pyoderma gangrenosum after infliximab serum sickness.
    Ariane M; Bouaziz JD; de Masson A; Jachiet M; Bagot M; Lepelletier C
    Dermatol Ther; 2019 Jan; 32(1):e12774. PubMed ID: 30341800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
    Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
    Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.